Jefferies ups estimates, price target for Pacira on Exparel outlook Things are going reasonably well for Pacira's ( PCRX ) local analgesic Exparel, Jefferies says. Although analyst Oren Livnat realizes "3rd party estimates aren’t ‘actuals'," he says "they’ve proven mostly conservative since launch," a good sign considering last month's IMS data. Livnat also "remains confident" in the drug's femoral nerve block potential (see here and here ). Q3, FY13, and FY14 ...
Oct. 1, 2013 - Seeking Alpha